Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study Meeting Abstract


Authors: Horwitz, S.; Whittaker, S.; Duvic, M.; Dummer, R.; Kim, Y. H.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Eradat, H.; Sanches, J.; Ortiz-Romero, P.; Akilov, O.; Trotman, J.; Taylor, K.; Dalle, S.; Weichenthal, M.; Walewski, J.; Fisher, D.; Wang, Y.; Palanca-Wessels, M. C.; Lin, H.; Liu, Y.; Little, M.; Prince, H. M.
Abstract Title: Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study
Meeting Title: 14th International Conference on Malignant Lymphoma
Journal Title: Hematological Oncology
Volume: 35
Issue: Suppl. 2
Meeting Dates: 2017 Jun 14-17
Meeting Location: Lugano, Switzerland
ISSN: 0278-0232
Publisher: Wiley Blackwell  
Date Published: 2017-06-07
Start Page: 245
End Page: 247
Language: English
ACCESSION: 123459876
DOI: 10.1002/hon.2438_109
PROVIDER: EBSCOhost
PROVIDER: cin20
DOI/URL:
Notes: Meeting Abstract: 249 -- Accession Number: 123459876 -- Entry Date: In Process -- Revision Date: 20170608 -- Publication Type: Article -- Supplement Title: Jun2017 Supplement -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20
Altmetric Score
MSK Authors
  1. Steven M Horwitz
    368 Horwitz